Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

Presentations

Investors

  • Investors Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Annual General Meeting
    • Email Alerts
  • Company Info
    • Company Profile
    • Management
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • Quote & Chart
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ASX Delisting
    • Conversion How-to

  • News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Annual General Meeting
  • Email Alerts
Apr 27, 2026 Corporate Overview April 2026
Apr 27, 2026 Investor Fact Sheet April 2026
Mar 27, 2026 Kazia Corporate Presentation March 2026
Mar 27, 2026 Investor Fact Sheet 2026
Oct 8, 2025 Kazia Corporate Presentation August 2025
May 22, 2025 Annual General Meeting May 2025
Feb 3, 2025 Kazia Corporate Presentation January 2025
rss_feed RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement